Koen van Besien, MD, PhD
-
Specialty: Hematology and Oncology
View Expertise -
Primary Location: 11100 Euclid Ave (0 mi.)
Other Locations - Languages Spoken: Dutch, English, French, German, Spanish
Office Locations
UH Seidman Cancer Center (0 mi.)
11100 Euclid Ave
1st Floor
Cleveland, OH 44106
216-844-3951
Biography: Koen van Besien, MD, PhD
Expertise
Titles
- Director, Wesley Center for Immunotherapy, UH Seidman Cancer Center
- Division Chief, Hematology and Cellular Therapy, UH Cleveland Medical Center
- Clinical Professor, CWRU School of Medicine
- Don C. Dangler Chair in Stem Cell Research, UH Seidman Cancer Center
Certifications & Memberships
- Hematology - American Board of Internal Medicine
- Medical Oncology - American Board of Internal Medicine
Education
Fellowship | Hematology/Oncology
Hematology/Oncology - Indiana University Hospital (1987 - 1990)
Other Education
Maastricht University (2006)
Medical Education
Katholieke Universiteit Leuven, Faculteit Der Geneeskunde (1984)
Featured Videos
Watch to find out more about this University Hospitals provider.
Patient Experience Reviews
Dr van Besien was superb. Knowledgeable, Friendly, Caring, Compassionate. It doesn't get any better!!!!!
It was good
One of my doctors was not good to me and left me very upset I will not be going back to her
Excellent care!
Support staff and nurses are very nice, respectful and attentive!
Doctor was very nice and helpful during this visit. Explained things we didn't quite understand and made them clear. Very happy with this provider, hospital and staff. It's been 7 years since I first found out I had cancer. The last bone marrow biopsy showed no evidence of ***. I am convinced that it will never appear again. My thankfulness and gratitude to everyone involved at Seidman! Thanks
Related Blog Articles
Rapid Rise to Cancer-Free Outcome
The first recipient of rapid novel CAR T-cell therapy was delighted by his treatment at UH.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Koen van Besien did not disclose any Outside Relationships with Industry.